Newsfeeds - Spark Newswire

1 minute read

Lexaria Announces DehydraTECH-CBD Versus Prescription CBD Program In Treating Seizures

Today, 10:04 PM

Lexaria Bioscience Corp (NASDAQ:LEXX) has commenced a new study to compare the effectiveness of Epidiolex to DehydraTECH-cannabidiol (CBD) for reducing seizure…

JAZZ

2 minute read

Lexaria Bioscience Reports Recent Oral THC Absorption Study Revealed Its DehydraTECH Required 15 Mins. To Deliver THC Levels In Blood Plasma

By Benzinga Newsdesk

Today, 10:04 PM

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that its recent oral tetrahydrocannabinol

LEXX

4 minute read

Uncategorized

LEXX: Lexaria’s DehydraTECH Shows Fast Delivery

By Zacks Small Cap Research

Today, 10:04 PM

By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT

BTI

6 minute read

Uncategorized

LEXX: An Investment That’s Easy to Swallow

By Zacks Small Cap Research

Today, 10:04 PM

By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT

LEXX

1 minute read

Lexaria Starts IND-Enabling Program For DehydraTECH-CBD For Hypertension

By Vandana Singh

Today, 10:04 PM

Lexaria Bioscience Corp (NASDAQ:LEXX) has formally begun the process towards an Investigational New Drug (IND) application filing with the FDA for…

LEXX

2 minute read

FDA
News

Lexaria Begins Investigational New Drug Enabling Program For DehydraTECH-CBD For Hypertension

By Benzinga Newsdesk

Today, 10:04 PM

Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms today announced it is formally beginning the process towards

LEXX

2 minute read

Lexaria Bioscience Corp. Releases Results Of Human Clinical Study Showing Effective, Safe BP Reduction With CBD

By InvestorBrandNetwork

Today, 10:04 PM

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced that its human clinical study HYPER-H21-2, which features LEXX’s patented DehydraTECH(TM)-processed cannabidiol (&l

LEXX

1 minute read

News

Why Lexaria Bioscience Shares Are Trading Higher Today

By Adam Eckert

Today, 10:04 PM

Lexaria Bioscience Corp (NASDAQ: LEXX) is trading higher Tuesday after the company announced initial results from its human clinical study of DehydraTECH, saying the study evidences up to 23% decrease in blood pressure with DehydraTECH-CBD relative to placebo.

LEXX

1 minute read

12 Health Care Stocks Moving In Tuesday’s Pre-Market Session

By Benzinga Insights

Today, 10:04 PM

ADAP

1 minute read

Lexaria Bioscience’s Formulated Cannabidiol Lowers Blood Pressure In Hypertension Patients

By Vandana Singh

Today, 10:04 PM

Lexaria Bioscience Corp (NASDAQ: LEXX) has announced initial results from human clinical study HYPER-H21-2 evaluating DehydraTECH-processed cannabidiol (CBD) for potential application against hypertension.

LEXX